JP2010507639A5 - - Google Patents

Download PDF

Info

Publication number
JP2010507639A5
JP2010507639A5 JP2009533934A JP2009533934A JP2010507639A5 JP 2010507639 A5 JP2010507639 A5 JP 2010507639A5 JP 2009533934 A JP2009533934 A JP 2009533934A JP 2009533934 A JP2009533934 A JP 2009533934A JP 2010507639 A5 JP2010507639 A5 JP 2010507639A5
Authority
JP
Japan
Prior art keywords
amino
cyclopentyl
alkyl
hydrogen
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009533934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507639A (ja
Filing date
Publication date
Priority claimed from GB0621205A external-priority patent/GB0621205D0/en
Priority claimed from GB0715614A external-priority patent/GB0715614D0/en
Application filed filed Critical
Priority claimed from PCT/GB2007/003998 external-priority patent/WO2008050096A1/en
Publication of JP2010507639A publication Critical patent/JP2010507639A/ja
Publication of JP2010507639A5 publication Critical patent/JP2010507639A5/ja
Withdrawn legal-status Critical Current

Links

JP2009533934A 2006-10-25 2007-10-19 癌の治療に有用なポロ様キナーゼ阻害剤としてのプテリジン誘導体 Withdrawn JP2010507639A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0621205A GB0621205D0 (en) 2006-10-25 2006-10-25 Inhibitors of PLK
GB0715614A GB0715614D0 (en) 2007-08-10 2007-08-10 Inhibitors of plk
PCT/GB2007/003998 WO2008050096A1 (en) 2006-10-25 2007-10-19 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2010507639A JP2010507639A (ja) 2010-03-11
JP2010507639A5 true JP2010507639A5 (enExample) 2010-12-02

Family

ID=38896021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533934A Withdrawn JP2010507639A (ja) 2006-10-25 2007-10-19 癌の治療に有用なポロ様キナーゼ阻害剤としてのプテリジン誘導体

Country Status (13)

Country Link
US (1) US20100216802A1 (enExample)
EP (1) EP2079743B1 (enExample)
JP (1) JP2010507639A (enExample)
KR (1) KR20090071668A (enExample)
AT (1) ATE542820T1 (enExample)
AU (1) AU2007310604B2 (enExample)
BR (1) BRPI0718120A2 (enExample)
CA (1) CA2665736A1 (enExample)
EA (1) EA200900593A1 (enExample)
IL (1) IL198082A0 (enExample)
MX (1) MX2009004244A (enExample)
NZ (1) NZ577153A (enExample)
WO (1) WO2008050096A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
BRPI0622100A2 (pt) * 2006-10-30 2011-12-27 Chroma Therapeutics Ltd hidroxamatos como inibidores de desacetilase de histona
CA2672612A1 (en) 2006-12-14 2008-06-26 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0807451D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
MX2011000021A (es) * 2008-06-23 2011-02-24 Vertex Pharma Inhibidores de proteina cinasas.
MX2011000026A (es) 2008-06-23 2011-02-24 Vertex Pharma Inhibidores de proteina cinasas.
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
AU2010291834A1 (en) * 2009-09-04 2012-03-15 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
PT3222616T (pt) 2012-10-17 2019-09-26 Macrophage Pharma Ltd N-[2-{4-[6-amino-5-(2,4-difluorobenzoíl)-2-oxopiridin-l(2h)-il]-3,5-difluorofenil}etil)-l-alaninato e o éster de terc-butilo do mesmo
EP2961403A4 (en) 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
US20160347750A1 (en) * 2014-01-31 2016-12-01 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
WO2020033823A1 (en) * 2018-08-10 2020-02-13 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
CN111039944B (zh) * 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CN115947728B (zh) * 2021-10-09 2024-01-09 沈阳药科大学 含磺酰基的二氢喋啶酮衍生物及其应用
EP4479042A1 (en) 2022-02-18 2024-12-25 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
CN118047779B (zh) * 2022-11-09 2025-02-11 沈阳药科大学 含苯联杂芳基的二氢喋啶酮衍生物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
JP2008510771A (ja) * 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用

Similar Documents

Publication Publication Date Title
JP2010507639A5 (enExample)
JP2010505802A5 (enExample)
JP2008540390A5 (enExample)
JP2009535387A5 (enExample)
JP2009535385A5 (enExample)
JP2011518816A5 (enExample)
CA2537135A1 (en) Pyrimidothiophene compounds
JP2008540389A5 (enExample)
JP2004517087A5 (enExample)
JP2013537907A5 (enExample)
JP2010508362A5 (enExample)
JP2009526830A5 (enExample)
JP2009525287A5 (enExample)
JP2009501732A5 (enExample)
JP2010508361A5 (enExample)
JP2011513305A5 (enExample)
JP2008540687A5 (enExample)
JP2008509166A5 (enExample)
JP2005537248A5 (enExample)
JP2014500265A5 (enExample)
JP2002521334A5 (enExample)
JP2015510886A5 (enExample)
EP2580209A4 (en) INHIBITORS OF HCV NS5A PROTEIN
ATE443713T1 (de) Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
CA2553879A1 (en) Viral polymerase inhibitors